AA
XLRN

ALPS Advisors’s Acceleron Pharma XLRN Stock Holding History

ALPS Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-76,386
Closed -$8.6M – 896
2020
Q3 		$8.6M Buy
76,386
+2,965
+4% +$295K 0.13% 138
2020
Q2 		$7M Sell
73,421
-13,244
-15% -$1.28M 0.09% 135
2020
Q1 		$7.79M Sell
86,665
-20,193
-19% -$1.57M 0.12% 118
2019
Q4 		$5.67M Buy
106,858
+1,466
+1% +$66.8K 0.04% 150
2019
Q3 		$4.16M Sell
105,392
-4,440
-4% -$193K 0.03% 158
2019
Q2 		$4.51M Sell
109,832
-14,654
-12% -$607K 0.03% 161
2019
Q1 		$5.8M Buy
124,486
+17,744
+17% +$779K 0.04% 152
2018
Q4 		$4.65M Buy
106,742
+25,335
+31% +$1.27M 0.04% 157
2018
Q3 		$4.66M Buy
81,407
+14,975
+23% +$736K 0.03% 167
2018
Q2 		$3.22M Buy
66,432
+5,762
+9% +$210K 0.02% 197
2018
Q1 		$2.37M Buy
60,670
+10,545
+21% +$448K 0.02% 199
2017
Q4 		$2.13M Buy
50,125
+12,098
+32% +$454K 0.01% 193
2017
Q3 		$1.42M Buy
38,027
+3,174
+9% +$110K 0.01% 214
2017
Q2 		$1.06M Buy
34,853
+2,380
+7% +$69K 0.01% 226
2017
Q1 		$860K Sell
32,473
-3,801
-10% -$100K 0.01% 230
2016
Q4 		$926K Sell
36,274
-11,656
-24% -$369K 0.01% 225
2016
Q3 		$1.74M Sell
47,930
-4,357
-8% -$144K 0.01% 192
2016
Q2 		$1.78M Buy
52,287
+10,569
+25% +$344K 0.02% 177
2016
Q1 		$1.1M Sell
41,718
-2,087
-5% -$60.7K 0.01% 185
2015
Q4 		$2.14M Sell
43,805
-7,942
-15% -$286K 0.02% 172
2015
Q3 		$12.9K Buy
51,747
+19,188
+59% +$577K 0.01% 200
2015
Q2 		$1.03M Buy
32,559
+16,486
+103% +$532K 0.01% 213
2015
Q1 		$612K Buy
+16,073
New +$639K 0.01% 212

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ALPS Advisors's XLRN Position: Q4 2020 in Review

ALPS Advisors sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 76,386 shares — an estimated $8.6M sold.

ALPS Advisors first reported a position in XLRN in Q1 2015 and held it in 23 quarters. The position peaked at $8.6M in Q3 2020. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

  • ALPS Advisors reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
  • ALPS Advisors sold 76,386 Acceleron Pharma shares in Q4 2020, an estimated $8.6M.
  • ALPS Advisors first reported a position in Acceleron Pharma in Q1 2015 and held it in 23 quarters.
  • ALPS Advisors's Acceleron Pharma position peaked at $8.6M in Q3 2020.
  • 253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on ALPS Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.